D050130ProceduresE02.095.60120410.968118Oncolytic Virotherapyprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonRadiation and Cellular Oncology32394753Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL, Guise T, Prabhkar BS, Kaul K, Schreiber H, Seth PHuman gene therapyLyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Hum Gene Ther. 2020 08; 31(15-16):863-880.Hum Gene Ther2020-06-12T00:00:002020LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor ß Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.32669371Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, Cohen EEW, Radcliffe HS, Gumuscu B, Cheng J, Snyder W, Siu LLClinical cancer research : an official journal of the American Association for Cancer ResearchTalimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clin Cancer Res. 2020 10 01; 26(19):5153-5161.Clin Cancer Res2020-07-15T00:00:002020Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.32657154Bernstock JD, Bag AK, Fiveash J, Kachurak K, Elsayed G, Chagoya G, Gessler F, Valdes PA, Madan-Swain A, Whitley R, Markert JM, Gillespie GY, Johnston JM, Friedman GKHuman gene therapyDesign and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Hum Gene Ther. 2020 10; 31(19-20):1132-1139.Hum Gene Ther2020-08-17T00:00:002020Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.35998300Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas HJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540.J Clin Oncol2022-08-23T00:00:002022Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.1.606530.027491520research area of0.9434040.086164957subject area for37236967Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, Onsu KA, Martin NT, Hoskin V, Ghahremani M, Marotel M, Marius R, He X, Crupi MJF, Hoang HD, Nik-Akhtar A, Ahmadi M, Zamani NK, Golshani A, Alain T, Greer P, Ardolino M, Dickinson BC, Tai LH, Ilkow CS, Bell JCNature communicationsSynthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nat Commun. 2023 05 26; 14(1):3035.Nat Commun2023-05-26T00:00:002023Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.BSD MicrobiologyPathologyUniversity of ChicagoKarenKaulKaren Kaul41.78927490000000-87.601250000000001025Kaul, KarenClinical ProfessorBernardRoizman1Wd7BaAHHaLLnnN+bUfg02fp+4Wo6r1Xc3h9eaOOFmI=Bernard Roizman41.78927490000000-87.601250000000001112Roizman, BernardEmeritus/Emerita, ProfessorRichardWhitleyRichard Whitley41.78927490000000-87.601250000000001238Whitley, RichardRalph R.WeichselbaumxXB+DqgWEf/5hHlsaUXv9Gq0+s+oRalph R. Weichselbaum41.78927490000000-87.601250000000002521Weichselbaum, Ralph R.ProfessorThomas F.GajewskiThomas F. Gajewski41.78927490000000-87.60125000000000355Gajewski, Thomas F.Professortrue1true1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessor